0      0

AM21-44: Assessment and Treatment of COVID-19 Coagulopathy

‐ Oct 19, 2021 3:45pm

Expiration Date: Dec 31, 2023

Credits: None available.

This program will describe what is currently known about the unique thrombo-inflammatory coagulopathic response associated with SARS-CoV2 infection, how it is uniquely different from other thrombotic disorders, and how current testing strategies including the use of thromboelastography/rotational thromboelastometry can be used to assess or to understand COVID-19 associated coagulopathy. Finally. anticoagulant strategies to prevent and treat COVID-19 associated coagulopathy will be evaluated, along with discussion of the latest clinical treatment trial results.

To view Spanish or English subtitles, click the "CC" box in the video player.
Para ver subtítulos en español o inglés, haga clic en el cuadro "CC" en el reproductor de video.

Learning Objectives:

  • Describe the thrombo-inflammatory response associated with COVID-19 coagulopathy and how it is different from other thrombotic disorders
  • Describe testing approaches to assess COVID-19 coagulopathy
  • Describe the latest anticoagulant strategies for the prevention and treatment of COVID-19 coagulopathy




  • Cyril Jacquot, MD, PhD:
    Nothing to Disclose
  • Adam Cuker, MD, MS:
    Consultant: Synergy; Royalties: UpToDate; Grant/Research Support: Alexion, Bayer, Novartis, Novo Nordisk, Pfizer, Sanofi, Spark, Takeda
  • Edward Wong, MD:
    Stock Shareholder, Full-time/Part-time Employee: Quest Diagnostics

All relevant financial relationships have been mitigated. By completing the evaluation, you are attesting to watching the presentation in its entirety. A certificate will be immediately provided after submission.

Credits Available

AM21-44: Assessment and Treatment of COVID-19 Coagulopathy Evaluation